Is Egrifta (Tesamorelin) Legal in Arizona?

What Egrifta (Tesamorelin) Is and Why the Legal Question Arises

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). Unlike synthetic HGH (somatropin), tesamorelin stimulates the pituitary to release the body's own growth hormone in a pulsatile, physiologic pattern rather than supplying exogenous hormone directly. This distinction matters legally and clinically.

The FDA granted approval to Egrifta (tesamorelin 2 mg) in November 2010 under NDA 022505, specifically for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy [1]. A higher-strength formulation, Egrifta SV (tesamorelin 2 mg/0.36 mL), received supplemental approval in 2019 [2]. Because it is an approved drug, tesamorelin sits in an entirely different legal category from research peptides such as BPC-157 or CJC-1295, which have no FDA approval.

Why People Wonder About Legality

Confusion arises for two reasons. First, tesamorelin is sometimes grouped with unapproved peptides in online wellness communities. Second, FDA enforcement actions in 2023 and 2024 placed several peptides on the "bulk drug substances that may not be compounded" list, rattling the broader peptide market. Tesamorelin was not placed on that prohibited list as a standalone active pharmaceutical ingredient in the same enforcement cycle that targeted, for example, BPC-157 and TB-500. Its approved-drug status actually gives it a clearer legal pathway than any unapproved research peptide.

Federal vs. State Legal Framework at a Glance

Federal law governs tesamorelin's drug approval, compounding rules, and interstate commerce. State law governs who may prescribe it in Arizona and how Arizona-licensed pharmacies may dispense it. The two layers work together, not against each other. No Arizona statute singles out tesamorelin for special restriction.

Federal Legal Status of Tesamorelin

Tesamorelin is not a controlled substance under the federal Controlled Substances Act (21 U.S.C. §812) [3]. The DEA Schedule listing process applies to substances with abuse potential; GHRH analogues have not been scheduled. A prescribing physician therefore does not need a DEA registration specifically for tesamorelin, and pharmacies do not need controlled-substance dispensing protocols to fill it.

FDA-Approved Drug Status

NDA 022505 established tesamorelin as an approved new drug product. That status means:

• The drug may be manufactured, marketed, and dispensed in the United States.
• Off-label prescribing by licensed physicians is legal under longstanding FDA policy [4].
• A prescription is required (Rx-only); over-the-counter sale is not permitted.

The FDA's Prescribing Information for Egrifta SV states the approved indication as "treatment of excess abdominal fat in HIV-infected patients with lipodystrophy" and specifies the dose as 2 mg subcutaneous injection once daily [2].

Compounding Status Under 503A and 503B

Because tesamorelin is an approved drug, compounded versions occupy a specific legal niche. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed 503A pharmacy may compound tesamorelin for an individual patient when a valid prescription is present, provided the compounded preparation is not "essentially a copy" of the commercially available product without a documented clinical reason [5].

A 503B outsourcing facility may compound tesamorelin in bulk for office use under slightly different requirements, including registration with the FDA and adherence to current good manufacturing practice (cGMP) standards [6].

The key practical takeaway: compounded tesamorelin from a properly registered 503A or 503B pharmacy is a legal product when dispensed against a valid prescription. Sourcing tesamorelin from an overseas research vendor or an unregistered domestic supplier is not legal.

Arizona State Legal Framework

Arizona follows the federal prescription-drug framework without adding extra layers of restriction on tesamorelin. The relevant state-level rules come from three bodies.

Arizona State Board of Pharmacy

The Arizona State Board of Pharmacy (A.R.S. Title 32, Chapter 18) licenses pharmacies and pharmacists operating in the state [7]. For a non-controlled prescription drug like tesamorelin, the requirements are:

1. A valid prescription order from a licensed prescriber.
2. Dispensing by or under the supervision of a licensed pharmacist.
3. Proper labeling per A.R.S. §32-1968.

No special permit, Schedule-specific registration, or board waiver is required. Arizona-licensed 503A compounding pharmacies must also hold a valid compounding license from the Board and comply with USP <795> standards for non-sterile preparations or USP <797> for sterile injectable preparations.

Arizona Medical Practice Act

The Arizona Medical Practice Act (A.R.S. Title 32, Chapter 13) governs what licensed physicians may prescribe [8]. Physicians licensed by the Arizona Medical Board may prescribe any FDA-approved or legally compounded drug within the scope of their clinical judgment, including off-label uses. The Act does not restrict tesamorelin prescribing to infectious-disease specialists. A family-medicine physician, internist, or endocrinologist with appropriate training may prescribe it.

Telehealth prescribing in Arizona is governed by A.R.S. §36-3601 et seq. Arizona law explicitly permits telemedicine consultations that culminate in a valid prescription, provided the prescriber establishes a proper patient-physician relationship, conducts an appropriate evaluation, and maintains records [9].

What Arizona Does Not Restrict

Arizona has not passed legislation specifically targeting GHRH analogues or growth-hormone secretagogues. The state's Controlled Substances Act (A.R.S. Title 36, Chapter 27) mirrors the federal schedule with some state-specific additions, but tesamorelin appears on neither the federal nor the Arizona state controlled-substance schedule. Arizona also has not adopted the kind of anti-HGH statute language that some states use to restrict direct somatropin prescribing for cosmetic body composition purposes, and tesamorelin's mechanism as a secretagogue (not exogenous GH) places it outside those statutes in any case.

Clinical Evidence Supporting Tesamorelin Use

Understanding the evidence base helps patients and prescribers make informed decisions about whether a prescription is clinically appropriate.

Visceral Fat Reduction in HIV Lipodystrophy

The two key Phase 3 trials submitted for FDA approval enrolled a combined 806 HIV-infected adults with HAART-related visceral adiposity. At 26 weeks, tesamorelin 2 mg/day produced a mean 18% reduction in visceral adipose tissue (VAT) measured by CT scan compared to a 2% reduction with placebo (P<0.001) [10]. Trunk-to-limb fat ratio and waist circumference improved significantly as well.

A 52-week extension study showed sustained VAT reduction with continued therapy and return toward baseline within 12 weeks of discontinuation, confirming the need for ongoing treatment to maintain effect [11].

IGF-1 and Metabolic Markers

Tesamorelin raises serum IGF-1 as a downstream marker of GH pulse amplification. In the Phase 3 program, IGF-1 normalized from below-normal baseline values in a significant proportion of treated patients. Fasting glucose and HbA1c did not significantly worsen over 26 weeks, though monitoring is warranted in patients with pre-diabetes [10].

Emerging Evidence in Non-HIV Populations

Off-label interest in tesamorelin centers on its potential to reduce visceral fat and improve metabolic markers in non-HIV adults with central adiposity, including those with metabolic syndrome. A 12-month randomized trial by Falutz et al. In non-HIV adults (N=155) showed significant VAT reduction and improvements in triglycerides vs. Placebo [12]. These findings support the clinical rationale for off-label prescribing, though FDA approval for this population has not been granted.

The HealthRX clinical team uses a structured eligibility framework before recommending tesamorelin to any patient. Key criteria include documented visceral adiposity (waist circumference >102 cm in men, >88 cm in women, or CT-confirmed elevated VAT), absence of active malignancy, absence of pituitary disease, and normal fasting glucose or well-controlled type 2 diabetes. This framework is reviewed at every prescription renewal.

How to Get Egrifta (Tesamorelin) Legally in Arizona

Getting a lawful supply of tesamorelin involves three steps: a qualified prescriber, a valid prescription, and a licensed pharmacy. Arizona residents have several practical options.

Step 1: Find a Qualified Prescriber

Any Arizona-licensed physician (MD or DO) may prescribe tesamorelin. Relevant specialties include endocrinology, internal medicine, infectious disease, and hormone medicine. Telehealth platforms licensed to operate in Arizona, including HealthRX, provide consultations with physicians who hold active Arizona Medical Board licenses. A typical initial consultation reviews:

• Medical history and current medications
• Fasting metabolic panel, lipid panel, and IGF-1 level
• Body composition assessment or waist circumference
• Goals and informed consent including off-label status if applicable

The Endocrine Society's 2014 Clinical Practice Guideline on growth-hormone deficiency states: "We recommend against the use of GH or GHRH analogues in adults without documented GH deficiency or other approved indication unless within a clinical trial." [13] Prescribers at HealthRX apply this guidance by requiring objective evidence of clinical need before issuing a prescription.

Step 2: Obtain a Valid Prescription

The prescriber issues a written or electronic prescription specifying tesamorelin 2 mg subcutaneous injection once daily (or another dose based on individual titration), quantity, refills, and the dispensing pharmacy. No DEA number is required on the prescription because tesamorelin is not a controlled substance.

Step 3: Use a Licensed Pharmacy

Patients in Arizona may fill the prescription at:

• A retail pharmacy that stocks or can order brand-name Egrifta or Egrifta SV.
• A licensed 503A compounding pharmacy, in-state or out-of-state with proper interstate shipping compliance, when a compounded formulation is clinically indicated and the prescription specifies a reason it differs from the commercially available product.
• A licensed 503B outsourcing facility supplying a physician's office or clinic for office-administered injections.

Patients should verify that any compounding pharmacy holds current licensure from its home state board and, if it operates as a 503B facility, is registered with the FDA [6]. The FDA maintains a public list of registered outsourcing facilities at fda.gov.

What to Avoid

• Purchasing tesamorelin from overseas research-chemical websites. These products are not subject to FDA oversight and may be mislabeled, contaminated, or counterfeit.
• Accepting tesamorelin from a practitioner who does not issue a formal prescription and pharmacy order. This arrangement does not constitute legal dispensing under Arizona or federal law.
• Compounded tesamorelin from a pharmacy that is not registered for sterile compounding. Subcutaneous injections are sterile preparations and must meet USP <797> standards to be safe and lawful.

Prescribing Tesamorelin Off-Label in Arizona: What the Rules Say

Off-label prescribing is legal under federal law and Arizona medical practice standards. The FDA does not regulate the practice of medicine, and the Agency has consistently stated that physicians may prescribe approved drugs for unapproved indications [4].

Informed Consent Requirements

Arizona does not have a specific statute mandating a special informed-consent form for off-label prescriptions. Standard informed-consent principles apply: the physician must disclose the off-label nature of the use, available evidence, risks, benefits, and alternatives. A documented discussion in the medical record satisfies this requirement.

Insurance Coverage for Off-Label Use

Brand-name Egrifta is FDA-approved only for HIV lipodystrophy. Private insurers and Medicare Part D may deny coverage for off-label prescriptions. Patients pursuing tesamorelin for metabolic body composition improvement outside the approved indication should anticipate paying out-of-pocket or using a compounding pharmacy, where cost is typically lower than brand-name product.

The average wholesale price of Egrifta SV runs approximately $3,200 to $3,800 per 30-day supply at brand-name retail pricing. Compounded tesamorelin from a licensed 503A pharmacy may run $150 to $400 per month depending on the pharmacy and dose, though pricing varies widely and patients should obtain a direct pharmacy quote.

Monitoring and Safety Considerations

Legal access is only part of responsible tesamorelin use. Ongoing monitoring protects patients and is part of standard prescribing practice.

Baseline and Follow-Up Labs

Recommended baseline labs before starting tesamorelin include:

• Fasting glucose and HbA1c (tesamorelin may cause glucose elevation in susceptible patients)
• Serum IGF-1 (to establish baseline and guide dose titration)
• Fasting lipid panel
• Basic metabolic panel

Follow-up IGF-1 at 4 to 6 weeks confirms appropriate GH stimulation. Fasting glucose should be re-checked at 3 months. The Egrifta SV prescribing information recommends discontinuing tesamorelin if IGF-1 rises above 3.0 standard deviations for age and sex [2].

Contraindications

Absolute contraindications per the FDA label include:

• Active malignancy or history of malignancy
• Disruption of the hypothalamic-pituitary axis (tumor, surgery, trauma, or radiation)
• Pregnancy
• Known hypersensitivity to tesamorelin or mannitol

Physicians should review the full prescribing information before initiating therapy [2].

Common Adverse Effects

In the Phase 3 trials, the most common adverse effects occurring in >5% of tesamorelin-treated patients and more frequently than placebo were: injection-site reactions (25.3%), arthralgia (12.4%), extremity pain (6.1%), peripheral edema (6.1%), and myalgia (5.7%) [10]. Most injection-site reactions were mild and resolved without intervention.

Telehealth Access to Tesamorelin in Arizona

Arizona law explicitly allows telemedicine. Senate Bill 1109 (2021) and subsequent amendments to A.R.S. §36-3601 affirmed that a valid patient-physician relationship may be established via synchronous audio-video consultation, and that prescriptions issued after such a consultation are lawful [9].

A HealthRX telehealth visit for tesamorelin evaluation typically proceeds as follows:

1. Online intake form collecting medical history, current medications, and goals.
2. Laboratory order sent to a patient-service center near the Arizona patient's location.
3. Synchronous video consultation with an Arizona-licensed physician to review labs and examination findings.
4. Prescription issued electronically to a licensed pharmacy if the physician determines clinical appropriateness.
5. Monthly or quarterly follow-up visits to review labs and adjust the plan.

The physician at every step holds an active Arizona Medical Board license. The pharmacy used to fill the prescription holds active licensure in the relevant state(s). Both requirements are non-negotiable for a legally valid supply chain.